Tortoise Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Tortoise Investment Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-845	Closed	-$25.4K	–	1157
2025 Q3	$25.4K	Hold	845	–	–	﹤0.01%	480
2025 Q2	$30.7K	Hold	845	–	–	﹤0.01%	453
2025 Q1	$30.6K	Hold	845	–	–	﹤0.01%	441
2024 Q4	$35.5K	Hold	845	–	–	﹤0.01%	476
2024 Q3	$46.9K	Hold	845	–	–	﹤0.01%	416
2024 Q2	$34.7K	Hold	845	–	–	﹤0.01%	445
2024 Q1	$39.5K	Hold	845	–	–	﹤0.01%	409
2023 Q4	$40.4K	Hold	845	–	–	0.01%	386
2023 Q3	$30.1K	Hold	845	–	–	﹤0.01%	416
2023 Q2	$39K	Hold	845	–	–	0.01%	369
2023 Q1	$33.9K	Hold	845	–	–	0.01%	382
2022 Q4	$39.1K	Hold	845	–	–	0.01%	354
2022 Q3	$35K	Hold	845	–	–	0.01%	362
2022 Q2	$50K	Hold	845	–	–	0.01%	304
2022 Q1	$61K	Hold	845	–	–	0.01%	284
2021 Q4	$71K	Hold	845	–	–	0.01%	255
2021 Q3	$76K	Hold	845	–	–	0.02%	227
2021 Q2	$81K	Sell	845 -100	-11%	-$10.4K	0.02%	214
2021 Q1	$108K	Hold	945	–	–	0.02%	194
2020 Q4	$131K	Sell	945 -100	-10%	-$11.9K	0.03%	174
2020 Q3	$86K	Hold	1,045	–	–	0.02%	191
2020 Q2	$82K	Hold	1,045	–	–	0.02%	189
2020 Q1	$46K	Hold	1,045	–	–	0.01%	227
2019 Q4	$45K	Hold	1,045	–	–	0.01%	253
2019 Q3	$45K	Hold	1,045	–	–	0.01%	245
2019 Q2	$66K	Hold	1,045	–	–	0.02%	223
2019 Q1	$72K	Hold	1,045	–	–	0.02%	215
2018 Q4	$45K	Hold	1,045	–	–	0.01%	245
2018 Q3	$80K	Hold	1,045	–	–	0.02%	202
2018 Q2	$80K	Hold	1,045	–	–	0.02%	203
2018 Q1	$53K	Hold	1,045	–	–	0.01%	235
2017 Q4	$48K	Hold	1,045	–	–	0.01%	251
2017 Q3	$56K	Hold	1,045	–	–	0.02%	214
2017 Q2	$65K	Buy	1,045 +100	+11%	+$6.03K	0.02%	190
2017 Q1	$64K	Sell	945 -150	-14%	-$11.4K	0.02%	181
2016 Q4	$77K	Hold	1,095	–	–	0.03%	167
2016 Q3	$78K	Hold	1,095	–	–	0.03%	157
2016 Q2	$54K	Hold	1,095	–	–	0.02%	192
2016 Q1	$69K	Buy	1,095 +150	+16%	+$9.81K	0.02%	170
2015 Q4	$106K	Hold	945	–	–	0.04%	140
2015 Q3	$91K	Sell	945 -230	-20%	-$26.3K	0.03%	158
2015 Q2	$120K	Sell	1,175 -553	-32%	-$42.9K	0.05%	142
2015 Q1	$107K	Hold	1,728	–	–	0.04%	150
2014 Q4	$76K	Hold	1,728	–	–	0.03%	182
2014 Q3	$98K	Buy	+1,728	New	+$87K	0.04%	152

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Tortoise Investment Management's RARE Position: Q4 2025 in Review

Tortoise Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 845 shares — an estimated $25.4K sold.

Tortoise Investment Management first reported a position in RARE in Q3 2014 and held it in 45 quarters. The position peaked at $131K in Q4 2020. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Tortoise Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Tortoise Investment Management sold 845 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $25.4K.
Tortoise Investment Management first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 45 quarters.
Tortoise Investment Management's Ultragenyx Pharmaceutical position peaked at $131K in Q4 2020.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Tortoise Investment Management's 13F filing for Q4 2025, filed 6 Feb 2026.